TransCode Therapeutics, Inc.
RNAZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -45,560.49% | -112,079.16% | -129.72% | -13.37% |
| EV / EBITDA | 0.00 | 0.20 | 0.76 | -3.07 |
| Quality | ||||
| ROIC | 0.00% | -62.99% | -29.68% | -110.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.98 | 0.26 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 43.97% | -235,222.86% | 1.58% | 19.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 1.73 | 0.96 | 1.00 |
| Interest Coverage | 0.00 | 0.00 | -27,815.79 | -2,779.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -9,123.86 | -4,270.07 | 0.00 |